http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Kim, Taeeun,Ahn, Jin-Hee,You, Dalsan,Jeong, In-Gab,Hong, Bumsik,Hong, Jun Hyuk,Ahn, Hanjong,Lee, Jae Lyun Elsevier 2015 Clinical genitourinary cancer Vol.13 No.4
<P><B>Abstract</B></P> <P><B>Background</B></P> <P>The purpose of the study was to evaluate the efficacy of metastasectomy for urinary tract carcinoma (UTC) and to determine prognostic factors that affect survival.</P> <P><B>Patients and Methods</B></P> <P>Data from a total of 30 patients with metastatic UTC who underwent a metastasectomy between February 2000 and July 2014 were analyzed retrospectively. Time to disease progression (TTP) and overall survival (OS) from metastasectomy, and potential prognostic factors were evaluated.</P> <P><B>Results</B></P> <P>The lung was the most frequent site of metastasectomy (n = 24) followed by the liver (n = 3) and lymph nodes (n = 3). With a median follow-up duration of 54.2 months, the median TTP was 15.2 months and the median OS was 30.0 months (95% confidence interval, 15.1-42.9) with a 3-year survival rate of 41%. In multivariate analysis, initial stage IV disease (<I>P</I> = .047), pure urothelial pathology (<I>P</I> = .034), and nonpulmonary metastasectomy (<I>P</I> = .040) were independent prognostic factors for a shorter TTP. Nonpulmonary metastasectomy was an independent factor affecting OS (<I>P</I> = .001).</P> <P><B>Conclusion</B></P> <P>A metastasectomy has the potential to contribute to better oncologic outcome in select patients with metastatic UTC, especially those with a single rather than multiple and pulmonary rather than nonpulmonary metastases due to recurrent rather than initially metastatic urinary tract cancer.</P>
Lee, Jae-Lyun,Kim, Jeong Eun,Ahn, Jin-Hee,Lee, Dae-Ho,Lee, Jungshin,Kim, Choung-Soo,Hong, Jun Hyuk,Hong, Bumsik,Song, Cheryn,Ahn, Hanjong The Korean Cancer Association 2010 Cancer Research and Treatment Vol.42 No.1
<P>To assess the efficacy and safety of treating Korean patients with metastatic hormone-refractory prostate cancer (HRPC) using docetaxel plus prednisolone chemotherapy.</P>